This study is currently not recruiting participants.

A retrospective study of outcomes with chemotherapy in pancreatic cancer patients who progress after curative intent surgery

Investigating Chemotherapy for Pancreatic Cancer Progression

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to determine the benefit of systemic chemotherapy in patients who have disease progession after initial resection of pancreatic cancer. We will also determine the over all survival after this progression and the progression free survival which is time from starting chemotherapy after disease progression to evidence of worsening disease.

Detailed description of study

The purpose of this study is to determine the benefit of systemic chemotherapy in patients who have disease progession after initial resection of pancreatic cancer. We will also determine the over all survival after this progression and the progression free survival which is time from starting chemotherapy after disease progression to evidence of worsening disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: pancreatic cancer
  • Age: 100 years or below
  • Gender: All

This study investigates the use of systemic chemotherapy in patients whose pancreatic cancer has progressed after initial surgery. Pancreatic cancer is a type of cancer that starts in the pancreas, an organ that helps with digestion and blood sugar regulation. The study aims to understand how chemotherapy can affect the overall survival of these patients, meaning how long they live after their cancer has worsened.

Participants in this study will receive systemic chemotherapy, which is a treatment using drugs that travel through the bloodstream to reach cancer cells all over the body. The study will measure progression-free survival, which is the time from starting chemotherapy after the cancer has progressed to when the disease shows signs of getting worse.

  • Who can participate: Eligible participants are adults aged 18 and older with pancreatic cancer that has progressed following initial surgical treatment. Key eligibility factors include adequate organ function and no prior systemic chemotherapy for advanced disease.
  • Study details: Participants will receive systemic chemotherapy to evaluate its effects on pancreatic cancer that has progressed after surgery. The study will measure overall survival and progression-free survival, which is the time from starting chemotherapy to when the disease worsens.
Updated on 19 Feb 2024. Study ID: 1611068365

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team